Drug intelligence / Profile preview

punicalagin

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Punicalagin is a naturally occurring ellagitannin, a polyphenolic compound found primarily in pomegranate (Punica granatum) peel, but also in other plants like Terminalia and Combretum species. It has a large molecular weight (C48H28O30, 1084.7 g/mol) and exists as alpha and beta isomers. Punicalagin exerts antioxidant, anti-inflammatory, antiproliferative, anti-atherosclerotic, hepatoprotective, antimicrobial, neuroprotective, anti-hyperlipidemic, antidiabetic, gastroprotective, and potential anticancer effects. Mechanistically, it is known to inhibit the NF-κB pathway, suppressing the production of pro-inflammatory cytokines (such as IL-1β, IL-6, IL-8, IL-17A, and TNF-α), matrix metalloproteinases (MMP-1, MMP-13), and limiting inflammation-related cell proliferation and migration. Additional anticancer mechanisms involve inducing apoptosis and autophagy, downregulating proteins like Annexin A1 in tumor cells, and modulating fibroblast activation markers. Punicalagin is not an approved pharmaceutical drug but is being researched for potential therapeutic effects in conditions such as rheumatoid arthritis, colorectal cancer, and is proposed as a natural supplement ingredient[1][3][4][6][7][8].

Other names
punicalaginpunicalaginspunicalagin apunicalagin ba pomegranate ellagitanningranatidinepulchinenoside B4punicalagin (technical grade)alpha-punicalaginbeta-punicalagin
02

Targets

P4HB (Protein disulfide-isomerase)PDIA3 (Membrane-associated rapid response steroid-binding receptor)NSP13 (SARS-CoV-2 helicase)SrtA (Sortase A)ANXA1 (Annexin A1)IL10 (Interleukin-10)NEMO (NF-κB essential modulator)MMP1 (Matrix metalloproteinase-1)MMP13 (Matrix metalloproteinase-13)NF-κB

Beyond the preview

Go deeper on punicalagin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on punicalagin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call